Indeed, HER2-overexpressing breast tumours are often resistant to hormonotherapy and more sensitive to anthracycline-based and taxane-containing chemotherapy (Paik et al, 2000; Pritchard et al, 2008), so that all invasive breast cancer need an HER2 evaluation at diagnosis. This evidence concerns the gene ERBB2 and invasive breast carcinoma.